Comparative Pharmacology
Head-to-head clinical analysis: MICROSUL versus SULTEN 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROSUL versus SULTEN 10.
MICROSUL vs SULTEN-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MICROSUL inhibits bacterial dihydropteroate synthase, preventing folate synthesis, and also acts as a competitive antagonist of para-aminobenzoic acid (PABA).
Selectively inhibits type 5 phosphodiesterase (PDE5), enhancing cyclic guanosine monophosphate (cGMP) accumulation, leading to smooth muscle relaxation and vasodilation in the corpus cavernosum.
Adult: 160 mg/800 mg (trimethoprim/sulfamethoxazole) orally every 12 hours for 14 days; intravenous dosing: 8-10 mg/kg/day (as trimethoprim) divided every 6, 8, or 12 hours.
1 to 2 tablets (10-20 mg) orally once daily, preferably in the morning.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours; prolonged in renal impairment
Terminal elimination half-life is 12-15 hours; clinically, this supports once-daily dosing with steady state achieved in 3-5 days.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Primarily renal excretion of unchanged drug (approx. 70-80%) with the remainder as inactive metabolites (10-15% fecal, 5-10% biliary).
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic